Insmed (NASDAQ:INSM) CFO Sara Bonstein Sells 1,447 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein sold 1,447 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total transaction of $252,023.99. Following the completion of the transaction, the chief financial officer owned 80,506 shares of the company’s stock, valued at approximately $14,021,730.02. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Wednesday, January 7th, Sara Bonstein sold 1,678 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $293,767.46.
• On Tuesday, January 6th, Sara Bonstein sold 1,517 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $262,941.61.

Insmed Stock Performance

Shares of INSM stock opened at $170.27 on Friday. The stock’s 50-day moving average is $190.31 and its two-hundred day moving average is $151.37. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The firm has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period last year, the company earned ($1.27) earnings per share. Analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as “worth keeping an eye on,” which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
• Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
• Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Insmed during the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 81 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wolfe Research set a $167.00 target price on shares of Insmed and gave the company an “outperform” rating in a report on Thursday, December 18th. Cowen set a $241.00 price objective on shares of Insmed in a research report on Thursday, December 18th. The Goldman Sachs Group upped their target price on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a report on Monday, December 15th. Citigroup reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, Mizuho set a $212.00 price target on Insmed in a research report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus price target of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.